Ultragenyx Pharmaceutical (RARE) Long-Term Investments (2015 - 2026)

Ultragenyx Pharmaceutical (RARE) has 12 years of Long-Term Investments data on file, last reported at $121.0 million in Q1 2026.

• Long-Term Investments for Q1 2026 came in at $121.0 million, up 76.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $121.0 million (up 76.48% YoY), and the FY2025 annual result was $57.0 million, down 57.78% from the prior year.
• Long-Term Investments rose to $121.0 million in Q1 2026 per RARE's latest filing, from $57.0 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $215.5 million in Q1 2022 and troughed at $2.8 million in Q4 2022.
• A 5-year average of $97.1 million and a median of $85.2 million in 2023 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2024 and 2025: Long-Term Investments soared 4113.48% in 2024, then plunged 89.13% in 2025.
• A 5-year view of Long-Term Investments shows it stood at $2.8 million in 2022, then grew by 14.14% to $3.2 million in 2023, then soared by 4113.48% to $135.0 million in 2024, then sank by 57.78% to $57.0 million in 2025, then soared by 112.28% to $121.0 million in 2026.
• Business Quant data shows RARE's Long-Term Investments at $121.0 million in Q1 2026, $57.0 million in Q4 2025, and $22.1 million in Q3 2025.